International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 755-760, 1 March 2010

External Beam Radiotherapy for Prostate Cancer Patients on Anticoagulation Therapy: How Significant is the Bleeding Toxicity?

Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Los Angeles, CA, October 28 to November 1, 2007.

  • Kevin S. Choe, M.D., Ph.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL
  • ,
  • Ashesh B. Jani, M.D.

      Affiliations

    • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA
  • ,
  • Stanley L. Liauw, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL
    • Corresponding Author InformationReprint requests to: Stanley L. Liauw, M.D., Department of Radiation and Cellular Oncology, University of Chicago Hospitals, 5758 S. Maryland Ave., MC 9006, Chicago, IL 60637. Tel: (773) 702-6870; Fax: (773) 834-7340

Received 23 December 2008; received in revised form 4 February 2009; accepted 12 February 2009. published online 21 May 2009.

Purpose

To characterize the bleeding toxicity associated with external beam radiotherapy for prostate cancer patients receiving anticoagulation (AC) therapy.

Methods and Materials

The study cohort consisted of 568 patients with adenocarcinoma of the prostate who were treated with definitive external beam radiotherapy. Of these men, 79 were receiving AC therapy with either warfarin or clopidogrel. All patients were treated with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy. Bleeding complications were recorded during treatment and subsequent follow-up visits.

Results

With a median follow-up of 48 months, the 4-year actuarial risk of Grade 3 or worse bleeding toxicity was 15.5% for those receiving AC therapy compared with 3.6% among those not receiving AC (p < .0001). On multivariate analysis, AC therapy was the only significant factor associated with Grade 3 or worse bleeding (p < .0001). For patients taking AC therapy, the crude rate of bleeding was 39.2%. Multivariate analysis within the AC group demonstrated that a higher radiotherapy dose (p = .0408), intensity-modulated radiotherapy (p = 0.0136), and previous transurethral resection of the prostate (p = .0001) were associated with Grade 2 or worse bleeding toxicity. Androgen deprivation therapy was protective against bleeding, with borderline significance (p = 0.0599). Dose–volume histogram analysis revealed that Grade 3 or worse bleeding was minimized if the percentage of the rectum receiving ≥70 Gy was <10% or the rectum receiving ≥50 Gy was <50%.

Conclusion

Patients taking AC therapy have a substantial risk of bleeding toxicity from external beam radiotherapy. In this setting, dose escalation or intensity-modulated radiotherapy should be used judiciously. With adherence to strict dose–volume histogram criteria and minimizing hotspots, the risk of severe bleeding might be reduced.

Prostate cancer, bleeding toxicity, anticoagulation therapy, warfarin, radiotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest: none.

PII: S0360-3016(09)00253-3

doi:10.1016/j.ijrobp.2009.02.026

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 755-760, 1 March 2010